

PROGENICS PHARMACEUTICALS INC  
Form 8-K  
October 11, 2018

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 11, 2018**

---

**Progenics Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

---

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>000-23143</b> (Commission File Number)	<b>13-3379479</b> (IRS Employer Identification No.)
--	--	---

**One World Trade Center, 47th Floor, New York, New York 10007**

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: **(646) 975-2500**

**Not Applicable**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 7.01. Regulation FD Disclosure.**

On October 11, 2018, Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) issued a press release announcing the Company’s plans to advance I-131 1095, the Company’s prostate specific membrane antigen (PSMA)-targeted therapeutic, into a Phase 2 clinical study. I-131 1095 is a small molecule radiotherapeutic designed to selectively bind to the extracellular domain of PSMA, a protein that is expressed on prostate cancer cells. A copy of the foregoing press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

**Exhibit**

**Description**

<b>No.</b>	<b>Description</b>
99.1	<u>Press Release announcing the Company’s plans to advance I-131 1095 into a Phase 2 trial, dated October 11, 2018</u>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROGENICS PHARMACEUTICALS, INC.**

By: /s/ Patrick Fabbio  
Patrick Fabbio  
Senior Vice President and Chief Financial Officer  
(Principal Financial and Accounting Officer)

Date: October 11, 2018